The Northern Ireland Biobank: A Cancer Focused Repository of Science by Lewis, Claire et al.
The Northern Ireland Biobank: A Cancer Focused Repository of
Science
Lewis, C., McQuaid, S., Clark, P., McGuigan, T., Murray, P., Greene, C., ... James, J. (2018). The Northern
Ireland Biobank: A Cancer Focused Repository of Science. Open Journal of Bioresources, 5, [9]. DOI:
10.5334/ojb.47
Published in:
Open Journal of Bioresources
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
 © 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons
Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:29. Sep. 2018
Lewis, C, et al. 2018. The Northern Ireland Biobank: A 
Cancer Focused Repository of Science. Open Journal of 
Bioresources, 5: 9, DOI: https://doi.org/10.5334/ojb.47
%,25(6285&(623(1-2851$/2)
BIORESOURCE PAPER
The Northern Ireland Biobank: A Cancer Focused 
Repository of Science
Claire Lewis1, Stephen McQuaid1, Priscilla Clark1, Paul Murray1, Tracey McGuigan1, 
Christine Greene1, Bronagh Coulter1, Ken Mills2 and Jacqueline James1
1 The Northern Ireland Biobank, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK
2 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK
Corresponding author: Claire Lewis (claire.lewis@qub.ac.uk)
The Northern Ireland Biobank (NIB) was established in 2011 as a joint initiative between Queen’s  University 
Belfast and Belfast Health and Social Care Trust to provide the infrastructure for the standardised 
 collection and storage of high quality, well annotated human tissue samples, with matched bloods and 
bodily fluids to underpin cancer research in Northern Ireland and beyond. The NIB has been instrumental in 
supporting translational research locally, nationally and internationally with a number of key achievements 
to date. The vision of NIB is to develop an internationally recognised biobank network within Northern 
Ireland which collects, stores and distributes high quality, clinically annotated biospecimens for biomarker 
research to benefit cancer patients.
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Funding statement: NIB receives core funding from the Health and Social Care Research and Development 
Division of the Public Health Agency in Northern Ireland with charitable funding from Friends of the Cancer 
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(1) Bioresource Overview
Project description
The Northern Ireland Biobank (NIB) is currently a disease 
specific biobank and was awarded full ethical approval 
in August 2011 for the collection of tumour and non-
tumour control tissues and associated biospecimens 
from patients with a suspected or confirmed diagnosis 
of cancer [1]. The NIB prospective collection targets colo-
rectal, breast, prostate, gynaecological, lung, head and 
neck and haematological malignancies with linkage to 
robust de-identified clinico-pathological data. Donation 
is voluntary and requires written informed consent 
from patients in accordance with the Human Tissue 
Act (2004). Tissue sampled for NIB is always surplus to 
clinical need to ensure that patient diagnostics are not 
compromised.
NIB’s status as a fully ethically approved tissue bank 
offers substantial benefits for researchers who apply to use 
tissue procured by NIB. Subject to an application and sci-
entific peer review process, NIB’s ethical approval extends 
to UK studies receiving non-identifiable tissue and data 
from the bank; eliminating the need for individual pro-
ject based ethical approval. NIB have a straightforward 
application system based on the UK’s Integrated Research 
Application System with efficient turnaround times, thus 
offering a significant advantage to researchers who are 
have traditionally faced lengthy delays when applying 
for individual project based approvals from local research 
ethics committees.
Key achievements of the NIB to date include:
•	 A rigorous regulatory framework which complies 
with research ethics and governance requirements for 
handling of human biospecimens for research. This 
provides timely release of samples to researchers with 
scientifically approved projects.
•	 Approval to utilise local NHS tissue pathology forma-
lin fixed paraffin embedded (FFPE) archive material to 
establish a series of ‘retrospective’ collections.
•	 The creation of novel resources including DNA librar-
ies and custom-built tissue microarrays from defined 
cohorts of FFPE tissues relocated to the NIB from the 
BHSCT pathology archives [2].
•	 Infrastructure to support individual requests from 
Chief Investigators for specific types of collections 
including fresh tissues for explant culture.
•	 A robust quality management system with regular 
audit across all aspects of NIB workflow.
NIB has been instrumental in providing the core infra-
structure and tissue access that has been critical to suc-
cessfully leveraging major external grant funding to 
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support translational research in Northern Ireland. NIB 
has also been instrumental in improving the quality and 
impact of research generated within the NI cancer research 
community [3–6]. This is reflected in the increased peer 
reviewed, high impact factored publications which have 
relied on NIB resources. Collaborations with local industry 
have also been forged through improved access to qual-
ity assured clinical samples. One NIB application made by 
Almac Diagnostics has contributed to the development 
of an assay to assess chemotherapy response in Breast 
Cancer. This research was published in the Journal of the 
National Cancer Institute and acknowledges the support 
given by the NIB [7].
Classification (1)
Human
Species
Human
Classification (2)
Biological samples and associated data.
Context
Spatial coverage
Centre for Cancer Research and Cell Biology, Belfast, 
Northern Ireland, United Kingdom.
Latitude: 54.585997
Longitude:	−5.944160
Temporal coverage
NIB consent and sample collection commenced in 
November 2011. There is no indicated end date.
Temporal coverage for accessibility
N/A
(2) Methods
Steps
NIB prospective collection from patients with solid 
tumour malignancies
NIB support a prospective collection of human biospeci-
mens from patients with solid tumour malignancies 
including: fresh and FFPE tumour and normal tissue; 
whole blood; plasma; serum; buffy coat; urine; saliva; bod-
ily fluids such as ascites or pleural fluid. The workflows 
associated with this collection are as follows:
1. NIB Clinical Research Nurses (CRN) or NIB 
 Technician liaise with the relevant clinical teams 
to identify patients with a suspected or confirmed 
diagnosis of cancer who are suitable for donation.
2. Patients are approached by NIB CRN or Technician 
and informed consent is sought.
3. Prior to surgery, NIB collect blood and other bodily 
fluids where appropriate.
4. Bloods are processed into their derivatives 
 according to NIB Standard Operating Procedures 
(SOPs) and placed into dedicated NIB storage.
5. Fresh tumour and normal tissue and FFPE is 
acquired through the local NHS tissue pathology 
laboratories. Where fresh tissue is to be collected, 
the specimen is brought fresh to the pathology 
laboratory for sampling by a Histopathologist or 
Advanced Biomedical Scientist trained in dissec-
tion. On lesser occasions, tissue may be sampled in 
theatre under direction of a Consultant Pathologist. 
Fresh tissue is immediately snap frozen following 
sampling.
6. The case is reviewed a Consultant Histopatholo-
gist who allocates two FFPE tumour blocks and two 
FFPE normal blocks to NIB.
7. Consent, sample collection, metadata and storage 
locations are all captured in the NIB’s Information 
Management System.
8. NIB Biomedical Scientist or NIB Technician under-
take tissue sectioning and nucleic acid extractions 
depending on study requests. Where a request has 
been made for FFPE tissue, NIB only release tissue 
sections to maximise future use of the parent block. 
Likewise, aliquots of blood/blood derivatives are 
made available dependent on the volume required 
by the study.
9. Matched de-identified clinic-pathological data is pro-
vided to the researcher upon study approval (for fur-
ther information, see ‘source of associated data’ below).
NIB prospective collection from patients with 
haematological malignancies
NIB supports a prospective collection of biospecimens 
from patients with haematological malignancies includ-
ing peripheral whole blood and bone marrow tissue. The 
workflows associated with this collection are as follows:
1. Patients are approached by a haematology clinician 
and informed consent is sought.
2. Peripheral whole blood and bone marrow is 
obtained by the haematology clinician for diagnos-
tic assessment. Any material surplus to diagnostic 
use will be donated to NIB.
3. Peripheral whole blood and bone marrow samples 
are processed according to NIB Standard Operating 
Procedures (SOPs) and placed into dedicated NIB 
storage facilities.
NIB retrospective collection
Retrieval of large cohorts of FFPE cancer tissues from the 
NHS diagnostic pathology archives has facilitated the cre-
ation of a unique set of resources for the NIB referred to as 
the ‘NIB retrospective collection’. With over 15,000 sam-
ples pulled from the archives to date, these samples have 
been used in specific study requests, to custom build tis-
sue microarrays (TMAs) and to create DNA libraries. The 
retrospective samples are enhanced by linkage with robust 
clinical and pathological data acquired from the Northern 
Ireland Cancer Registry. The blocks are retained in the 
secure NIB storage area but can be returned  immediately 
to the parent trust if required for further diagnostic 
testing. Tissue blocks are only sectioned by trained and 
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experienced NIB staff. All staff performing microtomy 
have received competency training, work to SOPs which 
includes instruction to always leave tissue on the block.
Stabilization/preservation
A variety of stabilization methods are utilised by NIB:
•	 FFPE tissue: Tissue is placed in 10% neutral buffered 
formalin until processed.
•	 Fresh tissue: Following sampling, fresh tissue is snap 
frozen in liquid nitrogen or pre-cooled isopentane. On 
request, fresh tissue can also be placed directly into media.
•	 Whole Blood, buffy coat and plasma: collected in Eth-
ylenediaminetetraacetic acid (EDTA) tubes.
•	 Serum: collected in a Serum Clot Activator tube.
•	 Bone Marrow: collected in EDTA tubes.
•	 For specific study requests NIB can facilitate the col-
lection of blood using tubes with stabilizing agents eg 
PAXgene tubes; Streck tubes.
•	 For specific study requests NIB can facilitate the col-
lection and immediate distribution of bodily fluids 
such as ascites or pleural fluid.
Type of long-term preservation
FFPE blocks and slides are stored at room temperature 
in a manual storage unit. Fresh frozen tissues and blood 
samples	are	 stored	at	−80°C;	DNA	aliquots	are	 stored	at	
−20°C.	Viable	cells	from	bone	Marrow	samples	are	stored	
in	liquid	nitrogen	units	(−196°C)
All samples are individually labelled with a unique sam-
ple identifier to ensure donor anonymity and are stored in 
a dedicated NIB storage facility. This facility has restricted 
access with remote wireless monitoring of room humid-
ity, room temperature, voltage and individual freezer tem-
peratures. An automated alert system warns NIB staff via 
telephone, email and text message of variation from pre-
set operating parameters.
Storage temperature
FFPE blocks, slides and TMAs are stored at room tempera-
ture. Fresh frozen tissue and aliquots of serum, plasma, 
whole	blood	and	buffy	coat	are	all	stored	at	−80°C.	DNA	is	
stored	at	−20°C.
Shipping temperature from patient/source to 
preservation or research use
Ambient temperature.
Shipping temperature from storage to research use
Frozen samples (tissue and/or blood derivatives) are 
shipped on dry ice. FFPE blocks and slides are transferred 
at ambient temperature.
Quality assurance measures
NIB operates a quality management system (QMS) to 
achieve continual quality improvement. Key aspects of the 
NIB QMS include:
•	 A dedicated lead for Quality Management who 
 oversees the QMS.
•	 A rigorous set of SOPS for the collection,  processing, 
storage and distribution of human  tissue and associ-
ated biospecimens. SOPs are based on best practice 
guidelines and/or best available evidence.
•	 Risk Assessments for the tissue and tissue handler.
•	 Staff induction, training and competency assessment 
to ensure staff are trained and competent in the skills 
specific to their job.
•	 Horizontal and vertical internal audits; participation in 
external quality assurance programs such as the Integrated 
Biobank of Luxembourg Proficiency Testing Scheme.
•	 All tissue is sampled and processed in a UKAS accred-
ited NHS tissue pathology laboratory (ISO 15189 Med-
ical Laboratory Accreditation).
•	 Pathological review of tissue including % tumour; 
nucleic acid qualification and quantification includ-
ing RIN/Qubit/Nanodrop where needed.
•	 A NIB Steering Committee meets at least twice a 
year to oversee the good practices of the NIB on an 
 ongoing basis.
Source of associated data
More commonly, NIB acquire de-identified clinico-path-
ological data from the Northern Ireland Cancer Registry 
(NICR). For each cancer type, NIB have developed core 
datasets which include long term follow up data where 
available. An example a dataset for lung cancer will include 
anonymised information on family history, smoking his-
tory, co-morbidities, overall stage, surgery and treatment 
details as well as recurrence information. NIB currently 
fund a full time member of staff who sits within the NICR 
to facilitate data linkage.
Data which is not available from the cancer registry may 
also be extracted for specific studies by clinicians or NIB 
NHS employed research nurses/technicians under the 
ethical approval granted to a particular study. Patients are 
not required to complete a data questionnaire at the time 
of consent or sample acquisition.
All data released to NIB approved studies is de-identi-
fied and linked to a unique code number at source; NIB 
never release data which contains information which 
could identify an individual.
Ethics Statement
NIB is a Health and Social Care Research Ethics Committee 
approved tissue bank. NIB were first awarded ethical 
approval by the Office of Research Ethics Northern Ireland 
(ORECNI) for the consent, collection, storage and distri-
bution of human tissue samples and associated data in 
March 2011 (OREC reference: 11/NI/0013). This approval 
was granted for five years and was renewed in 2016 (OREC 
reference 16/NI/0030).
NIB operate under the Queen’s University Belfast 
Human Tissue Authority Research License (MBC/BCH 
Research Licence 12044) for the removal, storage and use 
of human tissue for research.
NIB has generic and enduring ethics approval which 
enables researchers to use samples from the NIB prospec-
tive collection as long as the research falls within the remit 
of the NIB ethics approval. The ethics covers a wide variety 
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of research areas and tests. There are restrictions however 
on the use of tissues from the diagnostic tissue pathol-
ogy archives. For example, studies wishing to undertake 
whole genome sequencing of samples from the pathology 
archives will be required to obtain independent ethical 
approval. Studies where there is an intention to link the 
results to specific patient identifiers (family names etc) 
will not be supported by NIB.
Constraints
Currently NIB only consent donors who are receiving care 
in the Belfast Health and Social Care Trust.
(3) Bioresource description
Object name
Cancer
Bioresource name
The Northern Ireland Biobank
Bioresource acronym: NIB
Bioresource location
NIB is located within the Centre for Cancer Research and 
Cell Biology in Queen’s University Belfast. Patient consent 
and sample collection occurs within the Belfast Health 
and Social Care Trust. NIB currently have access to the 
tissue pathology archives of three of the four pathology 
departments in Northern Ireland.
Northern Ireland Biobank
Queen’s University Belfast
Centre for Cancer Research and Cell Biology
97 Lisburn Road
Belfast
BT9 7AE
Bioresource contact
NIB Administrator:
Tel: 028 90972915
Email: nibiobank@qub.ac.uk
Bioresource URL
http://www.nibiobank.org/
Identifier used
http://www.nibiobank.org/
Bioresource type
Cancer
Type of sampling
Disease based sampling
Anatomical site
NIB support targeted prospective collections in the 
 following cancer types:
•	 Colorectal
•	 Breast
•	 Prostate
•	 Gynaecology
•	 Head and Neck
•	 Lung
•	 Haematological malignancies
NIB can facilitate the retrieval of FFPE tissue blocks for all 
cancer types from diagnostic tissue pathology archives in 
Northern Ireland. See Table 1 for further information on 
the types of biospecimens collected by NIB.
Disease status of patients/source
Cancer
Clinical characteristics of patients/source
NIB consent both male and female patients who are over 
18 year of age with no upper age restriction. Patients 
must have a suspected or confirmed diagnosis of cancer 
and be able to provide informed consent. For the solid 
tumour prospective collection, blood samples (and urine 
or saliva if appropriate) are collected pre-surgery with 
 tissue  sampled from the surgical resection specimen. 
For the haematological prospective collection, blood and 
bone marrow samples are collected at the time of initial 
 investigation for cancer.
On request, NIB can also facilitate additional collection 
of blood samples, bodily fluids or tissue which is surplus 
to diagnostic need. For example, longitudinal collection 
of plasma for ctDNA analysis at time points during cancer 
treatment to determine response to therapy.
NIB’s access to diagnostic tissue pathology archives 
allows for retrieval of FFPE cohorts with varying clinical 
characteristics. NIB can facilitate retrieval of  diagnostic 
biopsies and resection tissue as well as metastatic tissue.
Size of the bioresource
NIB have prospectively consented >2770 donors and 
have accumulated over 90,000 samples as of February 
2018. The average annual recruitment is 462 donors 
per year.
As of February 2018, NIB have received 238 appli-
cations with over 40,350 samples released approved 
applications.
Recruitment and collection of biospecimens is ongoing 
with no indicated end date.
Vital state of patients/source
Alive
Clinical diagnosis of patients/source
Cancer
Pathology diagnosis
Variable	across	different	cancer	types	and	subtypes
Control samples
NIB routinely collect matched non-tumour control fresh 
and FFPE tissue from the donor resection specimen.
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Biospecimen type
Table 1: Overview of the types and numbers of samples 
collected by NIB.
Biospecimen Number of 
Aliquots/Blocks
Volume/
Size
Whole Blood 3 1 ml
Plasma 3 1 ml
Buffy Coat 1 N/A
Serum 2 1 ml
Urine 10 1 ml
Saliva 1 N/A
Fresh Frozen (tumour) 2 ~0.5 mm
3
Fresh Frozen (normal) 2 ~0.5 mm
3
FFPE (tumour) 2 N/A
FFPE (normal) 2 N/A
Bone Marrow Variable Variable
Bodily fluids (ascites; pleural 
fluid)
On request On request
Release date
N/A
Access criteria
Applications for NIB samples can be made by Chief 
Investigators from academia and healthcare that are inter-
nal and external to Northern Ireland. NIB also welcome 
industrial/commercial applications.
To access samples, Chief Investigators (CI) must com-
plete an electronic preliminary application via the NIB 
website. Details required in this preliminary applica-
tion include a scientific abstract, details of the Chief 
Investigator and Co-Investigators, source of funding, and 
the number and type of samples required. The purpose of 
the preliminary application is to:
•	 Allow NIB to determine if the study falls within the 
remit of NIB’s ethical approval;
•	 The required sample set is available within a realistic 
time-frame;
•	 There is evidence of sufficient funding to carry out the 
research.
The CI may be asked to pursue additional ethics approval 
should the study be deemed to fall outside of the remit of 
the NIB ethics approval. Following NIB internal review of 
the preliminary application the researcher will be asked to 
complete a full application and submit it with a detailed 
scientific protocol.
Applications are reviewed by two reviewers selected 
from the NIB Scientific Review Committee which com-
prises Consultant Histopathologists, clinicians, surgeons 
and basic scientists. Reviewers will complete a scientific 
review form which considers:
•	 Novelty
•	 Significance
•	 Study Design
•	 Research team and facilities
•	 Value	for	money
Based on the recommendations of the reviewers and any 
other project logistics and operational issues, the NIB 
Senior Team will either approve or reject the application. If 
the application is approved the applicant will receive formal 
NIB ethical approval. Chief Investigators must complete a 
Material Transfer Agreement before release of samples.
NIB’s access policy can be found on the NIB website: 
www.nibiobank.org.
(4) Reuse potential
NIB aliquot liquid samples so multiple samples will be 
available from the same donor to maximise sample use. 
Tissue sections or DNA/RNA aliquots from FFPE are dis-
tributed to research studies to ensure the block is avail-
able for future use. All sample metadata and associated 
donor clinico-pathological data is retained by NIB for use 
in other studies. NIB do not request the return of samples 
that have been distributed to research studies.
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